Nivolumab, ipilimumab, and cabozantinib for kidney cancer brain spread
Treatments studied
Part of Brain & nervous system, Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 2 study tests how well nivolumab plus ipilimumab, along with cabozantinib, treats untreated or worsening kidney cancer that has spread to the brain. It may help shrink brain tumors and slow the disease when standard local brain treatments aren’t the right option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and able to sign consent
- You must have brain metastases from kidney cancer that have not been treated yet (or worsened after SRS/surgery)
- Your brain tumors must be measurable on MRI (between 5 mm and 30 mm) and you need at least one target lesion
- You should not need steroids for brain symptoms for at least 10 days before starting (unless your symptoms are mild and stable)
- Your overall health and blood tests must be strong enough (bone marrow, liver, kidneys, and nutrition markers)
- You must be well enough to do daily activities (ECOG performance status 0 to 2) and you must be expected to live at least 12 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (tivozanib and nivolumab) for people with advanced kidney cancer that is not clear cell type. It aims to see if this drug pair can shrink or slow the cancer.
This Phase 2 study tests a “next-step” cabozantinib strategy for advanced kidney cancer (RCC) after your cancer previously responded to cabozantinib and then progressed. It aims to see if re-using cabozantinib in a planned sequence can control the cancer again with manageable side effects.
This study tests whether adding a drug called cabozantinib to standard nivolumab treatment helps fight kidney cancer that has spread to bone. It aims to understand how the bone environment changes during treatment.
This trial is testing a new treatment for people with advanced kidney cancer that has spread to other parts of the body. It aims to find a better way to manage the disease.
This Phase 2 study tests a different dosing schedule of cabozantinib (a cancer medicine) for metastatic kidney cancer and certain neuroendocrine tumors. It aims to see if the timing and schedule can work well for people with advanced disease.
This Phase 2 trial studies whether adding focused, high-precision radiation to immunotherapy helps people with advanced kidney cancer (that cannot be removed by surgery or has spread). It aims to improve cancer control by combining two treatment approaches.
Hear when a new Brain Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.